Programs Cancer and Gene Transfer Cancer is one of the leading causes of death in the United States.  New forms of therapy continue to be needed, and Tocagen believes a major avenue of next generation therapeutics will be based on gene transfer technology.   We are initially focused on programs for two cancer types, brain cancer (GBM) and malignant melanoma.     Programs  Brain Cancer (GBM)  Malignant Melanoma   Product Candidates  Prodrug Activator: Toca 511  Immunotherapeutic: Toca 621    Also see: Breakthrough Technology                                           Dictionary     Dictionary of Cancer Terms             Privacy Policy | Terms of Use | www.tocagen.com   3030 Bunker Hill St. Suite 230  San Diego, CA 92109          Main (858) 412-8400  Fax (858) 412-8499  © Copyright 2010 Tocagen Inc.